Evaluating Tocilizumab for Sever COVID-19 Infection in Breast Cancer vs. Non Cancer Pateints
Status:
Recruiting
Trial end date:
2022-08-26
Target enrollment:
Participant gender:
Summary
To compare evaluating Clinical outcomes for patients treated with Tocilizumab for sever
COVID-19 infection in breast cancer patients versus non cancer patients